Pyxis Oncology, Inc. (PYXS) Form S-3 — Aug 20, 2026
Pyxis Oncology filed an S-3 shelf registration covering the resale of up to 39,200,306 common shares held by selling stockholders from its July 2, 2026 private placement — 19,600,153 initial shares plus 19,600,153 shares underlying common warrants. The company receives no proceeds from any resale sales. The underlying PIPE sold shares at $2.551 with warrants struck at $3.289, raising roughly $50 million in gross proceeds.
Key figures
- Gross Proceeds
- None to company from stockholder resales; up to approximately $64.0 million in gross proceeds if Common Warrants are exercised in full for cash; ~$50 million gross proceeds already received in the July 2026 private placement
- Shares Offered
- 39200306
- Shares Outstanding
- 83408050
- Initial shares
- 19600153
- Warrant expiration
- July 2, 2029
- Common warrant shares
- 19600153
- Warrant exercise trigger
- Earlier of first public disclosure of MICVO Phase 1 monotherapy data in 2L+ R/M HNSCC or October 1, 2026
- Beneficial ownership limits
- 4.99% or 9.99% for most holders; GordonMD warrants have no beneficial ownership limitation
- Estimated total expenses usd
- 226756
- Resale shares vs outstanding
- 39,200,306 registered vs. 83,408,050 outstanding (~47%)
- Pipe purchase price per share
- 2.551
- Warrant exercise price per share
- 3.289
- Last reported sale price 2026 08 19
- 3.37
Price after filing
1 day: -1.3%7 days: +6.4%30 days: +6.7%
Close on the filing date to close N calendar days later (from $3.12). Historical, not a forecast.
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.